Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges

Journal of Cellular Biochemistry

Volumn 103, Issue 2, 2008, Pages 369-382

  Goncharova, Elena A ^a   Krymskaya, Vera P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Translational Research Laboratories   (United States)

Author keywords

Lung; Signal transduction; Smooth muscle; TSC1; TSC2; Tumor

Indexed keywords

GROWTH FACTOR; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; REGULATOR PROTEIN; S6 KINASE; TUBERIN; TUBEROUS SCLEROSIS 1 PROTEIN; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; GENDER; GENE MUTATION; HUMAN; LUNG TRANSPLANTATION; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ADULT; ANIMALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MALE; MICE; MICE, MUTANT STRAINS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; NEOPLASTIC SYNDROMES, HEREDITARY; PHOSPHORYLATION; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 38649143200     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21419     Document Type: Review

References (82)

1. Astrinidis A, Khare L, Carsillo T, Smolareck T, Au KS, Northrup H, Henske EP. 2000. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 37:55-57.
2. Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K. 2006. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 25:6361-6372.
3. Bhaskar PT, Hay N. 2007. The Two TORCs and Akt. Dev Cell 12:487-502.
4. Cai S-L, Walker CL. 2006. TSC2, a key player in tumor suppression and cystic kidney disease. Nephrol Ther 2:S119-S122.
5. Cai S-L, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL. 2006. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173:279-289.
6. Carsillo T, Astrinidis A, Henske EP. 2000. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97:6085-6090.
7. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. 2000. Molecular genetic advances in tuberous sclerosis. Hum Genet 107:97-114.
8. Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, Rosa JL, Guan K-L. 2006. TSC1 Stabilizes TSC2 by Inhibiting the Interaction between TSC2 and the HERC1 Ubiquitin Ligase. J Biol Chem 281:8313-8316.
9. Choo AY, Roux PP, Blenis J. 2006. Mind the GAP: Wnt Steps onto the mTORC1 Train. Cell 126:834-836.
10. Clevers H. 2006. Wnt/β-Catenin Signaling in Development and Disease. Cell 127:469-480.
11. Corradetti MN, Inoki K, Guan K-L. 2005. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 280:9769-9772.
12. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang J-a, Kumaki F, Darling T, Moss J. 2004. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 101:17462-17467.
13. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Karprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ. 2001. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68:64-80.
14. Demierre M-F, Higgins PDR, Gruber SB, Hawk E, Lippman SM. 2005. Statins and cancer prevention. Nature Rev Cancer 5:930-942.
15. Dong J, Pan D. 2004. Tsc2 is not a critical target of Akt during normal Drosophila development. Gene Dev 18:2479-2484.
16. Ellisen LW. 2005. Growth control under stress. Cell Cycle 4:e58-e60.
17. Findlay GM, Harrington LS, Lamb RF. 2005. TSC 1-2tumor suppressor and regulation of mTOR signalling: linking cell growth and proliferation? Curr Opin Genet Dev 15:69-76.
18. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM. 2006. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16:1865-1870.
19. Gan B, Melkoumian ZK, Wu X, Guan K-L, Guan J-L. 2005. Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size control. J Cell Biol 170:379-389.
20. Gan B, Peng X, Nagy T, Alcaraz A, Gu H, Guan J-L. 2006a. Role of FIP200 in cardiac and liver development and its regulation of TNFα and TSC-mTOR signaling pathways. J Cell Biol 175:121-133.
21. Gan B, Yoo Y, Guan J-L. 2006b. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of S6 kinase activation and cell growth. J Biol Chem 281:37321-37329.
22. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, Panettieri RA, Krymskaya VP. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis. J Biol Chem 277:30958-30967.
23. Goncharova E, Goncharov D, Noonan D, Krymskaya VP. 2004. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 167:1171-1182.
24. Goncharova EA, Goncharov DA, Krymskaya VP. 2006a. Assays for in vitro monitoring of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cell migration. Nat Protoc 1:2933-2939.
25. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP. 2006b. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 34:473-480.
26. Goncharova EA, Goncharov DA, Spaits M, Noonan D, Talovskaya E, Eszterhas A, Krymskaya VP. 2006c. Abnormal smooth muscle cell growth in lymphangioleiomyomatosis (LAM): Role for tumor suppressor T SC2. Am J Respir Cell Mol Biol 34:561-572.
27. Goncharova EA, Goncharov DA, Lim PN, Krymskaya VP. 2007. Simvastatin modulates RhoA activity, proliferation and migration of LAM-derived cells. Am J Respir Crit Care Med 175:A345.
28. Guertin DA, Guntur KVP, Bell GW, Thoreen CC, Sabatini DM. 2006a. Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol 16:958-970.
29. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. 2006b. Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCα, but Not S6K1. Dev Cell 11:859-871.
30. Haar EV, Lee S-i, Bandhakavi S, Griffin TJ, Kim D-H. 2007. Insulin signalling to mTOR mediated by the Akt/PKB substrate PR AS40. Nat Cell Biol 9:316-323.
31. Han S, Santos TM, Puga A, Roy J, Thiele EA, McCollin M, Stemmer-Rachamimov A, Ramesh V. 2004. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 64:812-816.
32. Hardie DG. 2007. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 47:185-210.
33. Harrington LS, Findlay GM, Lamb RF. 2005. Restraining PI3K: mTOR Signalling goes back to the membrane. Trend Biochem Sci 30:35-42.
34. Henske EP. 2003. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 38:376-381.
35. Hsu Y-C, Chern JJ, Cai Y, Liu M, Choi K-W. 2007. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445:785-788.
36. Inoki K, Corradetti MN, Guan K-L. 2005a. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19-24.
37. Inoki K, Ouyang H, Li Y, Guan K-L. 2005b. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 69:79-100.
38. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955-968.
39. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137.
40. Johnson SR. 2006. Lymphangioleiomyomatosis Eur Respir 27:1056-1065.
41. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. 2006. Molecular pathogenesis of lymphangioleiomyomatosis: Lessons learned from orphans. Am J Respir Cell Mol Biol 2006-0372TR.
42. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. 2003. Recurrent lymphangiomyomatosis after transplantation: Genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167:976-982.
43. Kleymenova E, Ibragimov-Beskrovnaya O, Kugoh H, Everitt J, Xu H, Kiguchi K, Landes G, Harris P, Walker C. 2001. Tuberin-dependent membrane localization of polycystin-1: A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 7:823-832.
44. Kobayashi E, Hirayama Y, Kobayashi E, Kubo Y, Hino O. 1995. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Ekert rat model of dominantly inherited cancer. Nat Genet 9:70-74.
45. Kobayashi E, Minowa O, Kuno J, Mitani H, Hino O, Noda T. 1999. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 59:1206-1211.
46. Kobayashi T, Minowa O, Sugitani Y, Takai S, Mitani H, Kobayashi E, Noda T, Hino O. 2001. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A 98:8762-8767.
47. Krymskaya VP. 2003. Tumor suppressors hamartin and tuberin: Intracellular signaling. Cell Signal 15:729-739.
48. Krymskaya VP. 2007. Smooth muscle-like cells in lymphangioleiomyomatosis. Proc Am Thorac Soc (In Press).
49. Krymskaya VP, Shipley JM. 2003. Lymphangioleiomyomatosis: A complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 28:546-550.
50. Kwiatkowski DJ. 2003. Tuberous sclerosis: From tubers to mTOR. Ann Human Genet 67:87-96.
51. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, Onda H. 2002. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11:525-534.
52. Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A. 2000. The TSC1 tumor suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2:281-287.
53. Lee C-H, Inoki K, Guan K-L. 2007. mTOR Pathway as a Target in Tissue Hypertrophy. Annu Rev Pharmacol Toxicol 47:443-467.
54. Li Y, Inoki K, Vacratsis P, Guan K-L. 2003. The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14- 3-3. J Biol Chem 278:13663-13671.
55. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. 2005. Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179-193.
56. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC. 2005. Feedback inhibition of Akt signaling limits the growth of tumors lackingTsc2. Gene Dev 19:1773-1778.
57. Murthy V, Han S, Beauchamp RL, Smith N, Haddad LA, Ito N, Ramesh V. 2004. Pam and its ortholog highwire interact with and may negatively regulate the TSC1/TSC2 complex. J Biol Chem 279:1351-1358.
58. Nobukini T, Thomas G. 2005. The mTOR/S6K signaling pathway: The role of the TSC1/2 tumor suppressor complex and the proto-oncogene Rheb. Novartis Found Symp 262:148-159.
59. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ. 1999. Tsc2+/- mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 104:687-695.
60. Polak P, Hall MN. 2006. mTORC2 Caught in a SINful Akt. Dev Cell 11:433-434.
61. Reiling JH, Hafen E. 2004. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Gene Dev 18:2879-2892.
62. Sabatini DM. 2006. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 6:729-734.
63. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A. 2005. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: Genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet 13:731-741.
64. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25:903-915.
65. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
66. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O. 2002. Mutational analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangileiomyomatosis. J Hum Genet 47:20-28.
67. Shaw RJ, Cantley LC. 2006. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430.
68. Shiota C, Woo J-T, Lindner J, Shelton KD, Magnuson MA. 2006. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11:583-589.
69. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. 1998. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: Chromosome 16p13 loss of heterozygosity in angiolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62:810-815.
70. Taveira-DaSilva AM, Moss J. 2006. Lymphangioleiomyomatosis. Cancer Control 13:276-285.
71. Um SH, D'Alessio D, Thomas G. 2006. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6 K1. Cell Metabol 3:393-402.
72. Vivekanand P, Rebay I, 2006. Intersection of signal transduction pathways and development. Annu Rev Genet 40:139-157.
73. Wilson C, Bonnet C, Guy C, Idziaszczyk S, Colley J, Humphreys V, Maynard J, Sampson JR, Cheadle JP. 2006. Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1+/- mice. Cancer Res 66:7934-7938.
74. Woodgett JR. 2005. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17:150-157.
75. Yang Q, Inoki K, Ikenoue T, Guan K-L. 2006. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20:2820-2832.
76. Yeung RS. 2003. Multiple roles of the tuberous sclerosis complex genes. Genes Chromosomes Cancer 38:368-375.
77. Yeung RS. 2004. Lessons from the Eker Rat Model: From cage to bedside. Curr Mol Med 4:799-806.
78. Yu J, Astrinidis A, Henske EP. 2001. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 164:1537-1540.
79. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112:1223-1233.
80. Zhe X, Schuger L. 2004. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 52:1537-1542.
81. Zhe X, Yang Y, Jakkaraju S, Schuger L. 2003. TIMP-3 downregulation in lymphangioleiomyomatosis: Potential consequence of abnormal SRF expression. Am J Respir Cell Mol Biol 28:504-511.
82. Zhe X, Yang Y, Schuger L. 2005. Imbalanced plasminogen system in lymphangioleiomyomatosis: Potential role of serum response factor. Am J Respir Cell Mol Biol 32:28-34.